IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Quantitative analysis updated February 25, 2026. Data-driven, not AI-generated.
Based on our 6-factor quantitative model, Xtant Medical Holdings, Inc. receives a Hold rating with a composite score of 57/100, ranking #975 out of 7,333 stocks in our coverage universe.
The stock scores particularly well on Short Interest (85th percentile). However, its weakest factor is Investment at just the 26th percentile, which investors should monitor.
On a valuation basis, XTNT trades at a 27% discount to its sector median P/E, suggesting the market may be underpricing the company's earnings power.
Our composite score is built from six academically-proven factors, each measured as a percentile rank across our entire coverage universe of 7,333 stocks. Higher percentile scores indicate stronger relative performance on that dimension.
Xtant Medical Holdings, Inc. shows solid profitability metrics that exceed the market median. Margins and returns on capital are healthy, suggesting a well-managed business with reasonable competitive positioning.
ROE: 16.0% · Gross Margin: 66.1% · Op. Margin: 7.6% · Net Margin: 3.9%
Xtant Medical Holdings, Inc. trades at a significant discount to intrinsic value based on multiple valuation frameworks. Price-to-earnings, price-to-book, and EV/EBITDA ratios all suggest the market is underpricing the company's fundamentals.
P/E: 16.2 · P/B: 1.7 · P/S: 0.6 · EV/EBITDA: 5.8
Xtant Medical Holdings, Inc. displays mixed momentum signals. Price action has been range-bound, with neither strong upward nor downward trends dominating recent trading activity.
Momentum percentile rank indicates price trend strength across 3, 6, and 12 month horizons.
Xtant Medical Holdings, Inc. is investing aggressively with high asset growth rates. While this may fuel future revenue expansion, academic evidence suggests that rapid investment intensity is often associated with lower subsequent returns.
Revenue Growth: 19.0% · D/E: 57.0%
Xtant Medical Holdings, Inc. shows below-average volatility relative to the market. The stock's return profile is relatively stable, offering a smoother ride for risk-conscious investors.
Beta: 0.61
Xtant Medical Holdings, Inc. has very low short interest relative to its float, indicating minimal bearish positioning by institutional investors. Low short interest often reflects broad consensus around the company's fundamental outlook.
Short interest as a percentage of float, relative to the market universe.
Xtant Medical Holdings, Inc. appears undervalued relative to its sector, trading at a 27% discount to the sector median P/E of 22.3x. This discount may represent an attractive entry point for value-oriented investors, though further analysis of growth expectations is warranted.
| Metric | XTNT | Manufacturing Median | vs. Sector |
|---|---|---|---|
| P/E Ratio | 16.2x | 22.3x | -27% |
| P/B Ratio | 1.7x | 2.6x | -36% |
| P/S Ratio | 0.6x | 2.4x | -74% |
| EV/EBITDA | 5.8x | 11.5x | -49% |
This stock exhibits below-average risk characteristics including low volatility, manageable debt, and stable return patterns. It may serve as a defensive holding in a diversified portfolio.
We'll email you when stocks you follow change their composite rating.
Comprehensive fundamental data for Xtant Medical Holdings, Inc. compared against Manufacturing sector medians. All data sourced from SEC filings and updated daily.
| Metric | XTNT | Manufacturing Median |
|---|---|---|
| Market Cap | $85M | -- |
| P/E Ratio | 16.2x | 22.3x |
| P/B Ratio | 1.7x | 2.6x |
| P/S Ratio | 0.6x | 2.4x |
| EV/EBITDA | 5.8x | 11.5x |
| Return on Equity | 16.0% | -1.9% |
| Return on Assets | 5.1% | 0.9% |
| Gross Margin | 66.1% | 44.1% |
| Operating Margin | 7.6% | 2.5% |
| Net Margin | 3.9% | 1.0% |
| Revenue Growth | 19.0% | 6.7% |
| Debt / Equity | 57.0% | 0.2% |
| Dividend Yield | 0.0% | 0.0% |
| Beta | 0.61 | -- |
Xtant Medical Holdings, Inc. currently receives a Hold rating, reflecting a balanced risk-reward profile. While the stock does not exhibit the strong multi-factor characteristics of our top-rated names, it also lacks the red flags that would warrant a more cautious stance. Existing shareholders may wish to maintain their positions while monitoring for improvements in the weaker factor scores. New investors may find better risk-adjusted opportunities elsewhere in the Manufacturing sector.
Disclaimer: This analysis is based on quantitative factor models and does not constitute personalized investment advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.